Sign up
Pharma Capital

ReNeuron's Michael Hunt discusses very encouraging long-term stroke data

Michael Hunt, chief financial officer at ReNeuron Group Plc (LON:RENE) updates Proactive on their phase II clinical study treating stroke patients with its CTX stem cells.

Hunt says the positive response rates reported at three months after treatment were sustained at 12 months after treatment, with seven people still showing a “clinically relevant improvement”.

 

View full RENE profile

ReNeuron Group Plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.